

PINPOINTING GLOBAL EXPERTISE IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)

Disease types associated with NAFLD present a tremendous research and development challenge for life sciences organizations and also a great opportunity for them to create value and innovation. The NASH market alone was valued at \$1,179 million in 2017, and is expected to reach \$21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025¹.

Digital Science offers the data capabilities to help information services leaders, discovery scientists, CI analysts, knowledge management, partnering and business development professionals uncover insights and expertise in disease-related topics and key indication areas.

What follows are some example insights in Nonalcoholic fatty liver disease (NAFLD) and its common disease type NASH (non-alcoholic steatohepatitis) extracted from our Dimensions platform.


¹<https://www.alliedmarketresearch.com/press-release/global-non-alcoholic-steatohepatitis-NASH-market-is-expected-to-reach-1-6-billion-by-2020-allied-market-research.html>



GLOBAL RESEARCH GRANTS IN NAFLD²

Since 2013, 42% of these grants have resulting publications we can identify with an average of 7.6 publications per grant.

BETWEEN 2008 AND 2018:



GLOBAL PUBLICATION ACTIVITY IN NAFLD

Altmetric attention could indicate a current treatment breakthrough in NAFLD.


For example, Jeff Schwimmer, Professor of Pediatrics at University of California, San Diego and Director of the Fatty Liver Clinic at Rady Children's Hospital San Diego, is a medical key opinion leader in paediatrics and NAFLD. He is active on Twitter.

Jeff Schwimmer @TheLiverPost - Nov 12

From @Duke_liverdoc Cenicriviroc treatment over 2 years results in clinically meaningful and sustained improvement in fibrosis in adults Nonalcoholic Steatohepatitis and sever liver fibrosis #LiverMtg18 @AASLDtweets

He points to promising results from HIV immunotherapy drug called Cenicriviroc for the reduction of fibrosis in patients with Nonalcoholic Steatohepatitis (NASH).

Publications:



² Based on awarded grants from over 260 funders indexed in the Dimensions database.

FINDING EXPERTS IN SPECIFIC BRANCHES OF NAFLD

NLP-driven search technology in Dimensions allows for the identification of experts using specific concepts. In this case, we explore NASH from specific perspectives.

THE FOLLOWING 5 KEY CONCEPTS WERE USED IN THIS WORKED EXAMPLE:



Both top experts Arun Sanyal and Geoffrey Farrell collaborated in a study which demonstrated the efficacy of an HIV immunotherapy called Centirivoc in the reduction of liver fibrosis in NASH patients. This is a recent breakthrough published in 2018³.

³ A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis Hepatology, 67(5), 1754-1767, 2018<https://doi.org/10.1002/hep.29477>

EXPERTS ARE REVEALED FROM PUBLICATIONS BASED ON THESE CONCEPTS:



Expert	Organization	Published From - Through	Publications Related To / Total
Arun Sanyal	Virginia Commonwealth University	1989-2018	51 / 676
Rohit Loomba	University of California, San Diego	2006-2018	56 / 287
Zobair M Younossi	Inova Fairfax Hospital	1995-2018	41 / 838
Anna Mae Diehl	Duke University	1982-2018	28 / 438

EXPERTS REVEALED FROM RESEARCH GRANTS BASED ON THESE CONCEPTS:

Expert	Organization	Funded From - Through	Grants Related / Total
Geoffrey Farrell	Australian National University	1994-2019	3 / 20
Narcissus Teoh	Australian National University	2010-2019	2 / 6
Tomoko Ishikawa	Ochanomizu University	2001-2022	2 / 12
Eiji Warabi	University of Tsukuba	2003-2020	5 / 38
Masato Yoneda	Yokohama City University	2010-2021	3 / 7

CLINICAL TRIAL AND PATENT TRENDS IN NAFLD ALSO FOUND IN DIMENSIONS


CLINICAL TRIALS IN NAFLD 2008-2018:



Our algorithm can automatically show publications which have been reported as "Publications of Results" from these clinical trials*

* Mainly from the Clinicaltrials.gov registry

Patents Published:



START YOUR STRATEGY

Contact Jennifer to start a strategic conversation on how our data capabilities can help your organization.

j.lewis-gallagher@digital-science.com